Vitality Biopharma Inc (OTCMKTS:VBIO) continues to be a unappreciated stock in the vibrant cannabis industry. It intends to aim NBS and IBD. Commencing in 2014, marijuana equities were in focus. Shareholders were analyzing the industry to list any firm that stated itself as an emerging entity in the buzzing cannabis market.
The shortcoming in that investment plan, though, was that many stockholders were too absent-minded while selecting a firm with an attractive title, rather than an entity that indeed boasted some substance. While investors were attracted by the illusion that profits would be fetched by putting money in these firms that purportedly envisioned to cultivate and sell recreational and medicinal based pot, they should have focused more on putting money in firms that are determined using the crop’s cannabinoid benefits, which are steadily exhibiting extraordinary advantage in curing certain medical ailments.
Having said that, if shareholders had only focused on seeking rewarding and realistic prospect via cannabis medications, Vitality Biopharma would have been regarded. It is one of 3 cannabinoid related entities that they witness as truly being able to produce any significant revenue in the forthcoming few years.
The so designated “green rush” that was in full swing in 2014 led investors to numerous penny shares, many of whom misguided stockholders with pipe dreams of attaining a position in the budding multi-billion-dollar pot business that has progressed through the legalization of pot laws in some of the states in the U.S. and abroad.
Another firm in the cannabis industry, Marapharm Ventures Inc. (OTCMKTS:MRPHF) has finalized a contract to acquire an industrial facility situated in southern California and 3 medicinal marijuana permits for retail, manufacturing and cultivate application.
In the last trading session, the stock price of MRPHF declined over 4% to close the day at $1.07. The decline came at a share volume of 67,330 compared to average share volume of 91,846.